Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
We found that ADAR1 was highly expressed in esophageal squamous cell carcinoma (ESCC). Knockdown of ADAR1 suppressed cell proliferation. Comprehensive analysis using microarrays suggested that ADAR1 may suppress the immune response and apoptosis and contribute to the survival of cancer cells. In ADAR1 knockdown cells, the binding between the target genes and cancer stimulating RBPs (csRBPs) were increased/decreased and then the amounts of mRNAs were altered. These results suggested that ADAR1 may cause A-to-I RNA editing in the 3’UTR of mRNAs that control cell growth, infiltration, and cancer immunity, and regulate association between csRBP and target mRNAs. In conclusion, ADAR1 may be a hub factor that induces disruption of the post-transcriptional regulatory mechanism in ESCC cells.
|